These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10918271)

  • 21. Mycophenolate mofetil for ocular myasthenia.
    Chan JW
    J Neurol; 2008 Apr; 255(4):510-3. PubMed ID: 18299952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case of severe refractory myasthenia gravis in HUKM.
    Hamizah R; Norlinah MI; Tan HJ; Soehardy Z; Halim AG; Rohana AG; Hamidon BB; Kong NC; Raymond AA
    Med J Malaysia; 2006 Dec; 61(5):633-5. PubMed ID: 17623968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.
    Hehir MK; Burns TM; Alpers J; Conaway MR; Sawa M; Sanders DB
    Muscle Nerve; 2010 May; 41(5):593-8. PubMed ID: 20405499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycophenolate mofetil treatment of myasthenia gravis.
    Cahoon WD; Kockler DR
    Ann Pharmacother; 2006 Feb; 40(2):295-8. PubMed ID: 16403848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Hart IK; Mantegazza R; Shukla SS; Siddiqi ZA; De Baets MH; Melms A; Nicolle MW; Solomons N; Richman DP
    Neurology; 2008 Aug; 71(6):400-6. PubMed ID: 18434638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.
    Meriggioli MN; Rowin J; Richman JG; Leurgans S
    Ann N Y Acad Sci; 2003 Sep; 998():494-9. PubMed ID: 14592919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical treatment options for ocular myasthenia gravis.
    Antonio-Santos AA; Eggenberger ER
    Curr Opin Ophthalmol; 2008 Nov; 19(6):468-78. PubMed ID: 18854691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone.
    ter Meulen CG; Gregoor PJ; Weimar W; Hilbrands LB
    Transpl Int; 2001; 14(2):99-102. PubMed ID: 11370174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycophenolate mofetil therapy in Taiwanese myasthenia gravis.
    Yeh JH; Chen WH; Chiu HC
    Acta Neurol Taiwan; 2008 Sep; 17(3):167-71. PubMed ID: 18975522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.
    Vernino S; Salomao DR; Habermann TM; O'Neill BP
    Neurology; 2005 Aug; 65(4):639-41. PubMed ID: 16116136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe skin reaction related to mycophenolate mofetil for myasthenia gravis.
    Levin N; Mali A; Karussis D
    Clin Neuropharmacol; 2005; 28(3):152-3. PubMed ID: 15965319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011).
    Wang A; Smith JR; Creevy KE
    J Small Anim Pract; 2013 Aug; 54(8):399-404. PubMed ID: 23879827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States.
    Burns TM; Sanders DB; Kaminski HJ; Wolfe GI; Narayanaswami P; Venitz J
    Muscle Nerve; 2015 May; 51(5):635-7. PubMed ID: 25704880
    [No Abstract]   [Full Text] [Related]  

  • 35. Mycophenolate mofetil: a new immunosuppressive approach. Successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection.
    Caponnetto C; Rossi E; Primavera A
    Eur Neurol; 2001; 46(1):53-4. PubMed ID: 11455187
    [No Abstract]   [Full Text] [Related]  

  • 36. [Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis].
    Greiner K; Varikkara M; Santiago C; Forrester JV
    Ophthalmologe; 2002 Sep; 99(9):691-4. PubMed ID: 12219257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycophenolate mofetil and myasthenia gravis.
    Ciafaloni E
    Lupus; 2005; 14 Suppl 1():s46-9. PubMed ID: 15803932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance immunosuppression in myasthenia gravis, an update.
    Morren J; Li Y
    J Neurol Sci; 2020 Mar; 410():116648. PubMed ID: 31901719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis.
    Dodd KC; Ahmed R; Ambrose P; Holt JK; Jacob S; Leite MI; Miller JA; San PP; Spillane J; Viegas S; Sussman J
    Neuromuscul Disord; 2024 May; 38():51-57. PubMed ID: 38626662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.
    Oskarsson B; Rocke DM; Dengel K; Richman DP
    Neurology; 2016 Mar; 86(12):1159-63. PubMed ID: 26850977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.